z-logo
open-access-imgOpen Access
Will 1,2-dihydro-1,2-azaborine-based drugs resist metabolism by cytochrome P450 compound I?
Author(s) -
Pedro J. Silva
Publication year - 2016
Publication title -
peerj
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.927
H-Index - 70
ISSN - 2167-8359
DOI - 10.7717/peerj.2299
Subject(s) - bioisostere , context (archaeology) , chemistry , pharmacophore , stereochemistry , enzyme , steric effects , aryl , active site , cytochrome p450 , combinatorial chemistry , biochemistry , chemical synthesis , organic chemistry , biology , alkyl , in vitro , paleontology
1,2-dihydro-1,2-azaborine is a structural and electronic analogue of benzene which is able to occupy benzene-binding pockets in T4 lysozyme and has been proposed as suitable arene-mimicking group for biological and pharmaceutical applications. Its applicability in a biological context requires it to be able to resist modification by xenobiotic-degrading enzymes like the P450 cytochromes. Quantum chemical computations described in this work show that 1,2-dihydro-1,2-azaborine is much more prone to modification by these enzymes than benzene, unless steric crowding of the ring prevents it from reaching the active site, or otherwise only allows reaction at the less reactive C 4 -position. This novel heterocyclic compound is therefore expected to be of limited usefulness as an aryl bioisostere.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom